|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07D 471/14 | |
| A61K 31/4745 | |||
| A61P 35/00 | |||
| A61P 37/00 | |||
| A61P 29/00 |
| (11) | Patento numeris | 3169687 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 15821295.1 |
| Europos patento paraiškos padavimo data | 2015-07-11 | |
| (97) | Europos patento paraiškos paskelbimo data | 2017-05-24 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-01-02 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2015/040076 |
| Data | 2015-07-11 |
| (87) | Numeris | WO 2016/010869 |
| Data | 2016-01-21 |
| (30) | Numeris | Data | Šalis |
| 201462024192 P | 2014-07-14 | US |
| (72) |
CHEN, Guoqing, Paul, US
YAN, Changren, US
REALE, Michael, US
CHEN, Monica, US
|
| (73) |
ADVENCHEN PHARMACEUTICALS, NANJING LTD.,
Room 302, Block A Pharmaceutical & Biology Incubator Building Entrepreneurship Center Nanjing New & High Tech Zone, Nanjing, Jiangsu 210061,
CN
|
| (54) | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS |
| FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS |